NADOLOL AND BENDROFLUMETHIAZIDE (bendroflumethiazide; nadolol) by Pfizer is clinical pharmacology nadolol nadolol is a nonselective beta-adrenergic receptor blocking agent. Approved for hypertension, to lower blood pressure, heart failure. First approved in 2008.
Drug data last refreshed 20h ago
CLINICAL PHARMACOLOGY Nadolol Nadolol is a nonselective beta-adrenergic receptor blocking agent. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood…
Worked on NADOLOL AND BENDROFLUMETHIAZIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.